A company driven to create positive change and reduce the impact of disease on people’s lives
Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and autoimmune diseases with a high unmet medical need.
With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Leading the way with our pioneering vaccines
VB10.16
VB10.16, Nykode’s wholly owned lead candidate, is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers. The cancer vaccine is designed based on Nykode’s Vaccibody™ technology platform of targeting antigens to antigen presenting cells.
VB10.NEO
The cancer neoantigen vaccine, VB10.NEO, is one of our lead product candidates and is exclusively out-licensed to Genentech, a member of the Roche Group. It is currently in a Phase 1b trial for the treatment of locally advanced and metastatic tumors.
Empowered by our long-standing partnerships
In our mission to bring our discoveries to the people who need them, we are proud to collaborate with world-class organizations. In oncology, our partners are Roche and Genentech, and further, we have a multi-target collaboration with Regeneron within oncology and infectious diseases.
